Heat Biologics, Inc. (NASDAQ:HTBX) Files An 8-K Other Events
Item 8.01. Other Events
Heat Biologics, Inc. (the Company) will be making several
investor presentations over the next several weeks. In connection
with the presentations, the Company intends to discuss the slide
presentation attached as Exhibit 99.1 hereto, which is
incorporated herein by reference.
The slide presentation attached as Exhibit 99.1 to this Report
includes safe harbor language to the Private Securities
Litigation Reform Act of 1995, as amended, indicating that
certain statements contained in the slide presentation or in the
press release are forward-looking rather than historical.
The Company undertakes no duty or obligation to update or revise
information included in this Report or any of the Exhibits.
Item 9.01 Financial Statements and Exhibits.
|
(d) |
Exhibits |
|
Exhibit No. |
Description |
|
|
99.1 |
Heat Biologics, Inc. investor presentation dated May 31, |
About Heat Biologics, Inc. (NASDAQ:HTBX)
Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC. Heat Biologics, Inc. (NASDAQ:HTBX) Recent Trading Information
Heat Biologics, Inc. (NASDAQ:HTBX) closed its last trading session down -0.004 at 0.698 with 206,748 shares trading hands.
